While previous studies focused on class II HLA alleles, such as HLA‐DRB1*15:01, this result highlights the need to incorporate the class I HLA‐E*01:01 allele when modeling multiple MHC components of MS risk, especially in the context of prior EBV infection. Here, HLA-E is linked to myeloid sarcoma.